Pfizer Azione

Pfizer Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di Pfizer (PFE) al 17 ago 2026 è 116,81 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 122,63 % — una variazione del -4,75% (inferiore).

Conversione FCF

116,81 %

YoY

-4,75%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Pfizer ammonta a 2026 116,81 % . Tasso di Conversione FCF (FCF/EBITDA) di Pfizer ammontava a 2025 122,63 % . Diminuisce del -4,75% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Pfizer Analisi delle Azioni

Cosa fa Pfizer? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Pfizer azioni

Tasso di Conversione FCF (FCF/EBITDA) di Pfizer è 116,81 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Pfizer è passato da 122,63 % a 116,81 %, con una variazione del -4,75 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Pfizer di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Pfizer di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Pfizer

Tutte le Metriche Finanziarie — Pfizer